Cargando…

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Tai, Wanbo, Zhang, Xiujuan, Drelich, Aleksandra, Shi, Juan, Hsu, Jason C., Luchsinger, Larry, Hillyer, Christopher D., Tseng, Chien-Te K., Jiang, Shibo, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403570/ https://www.ncbi.nlm.nih.gov/pubmed/32759966 http://dx.doi.org/10.1038/s41422-020-0387-5

Ejemplares similares

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
por: Shi, Juan, et al.
Publicado: (2022)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction
por: Cao, Wenpeng, et al.
Publicado: (2021)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355–359; 2020)
por: Jiang, Shibo, et al.
Publicado: (2020)

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2014)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
por: Liu, Xianglei, et al.
Publicado: (2020)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
por: Wang, Xinyi, et al.
Publicado: (2019)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
por: Du, Lanying, et al.
Publicado: (2008)

Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro
por: Curreli, Francesca, et al.
Publicado: (2020)

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
por: Zhang, Naru, et al.
Publicado: (2016)

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2
por: Ye, Gang, et al.
Publicado: (2020)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC
por: Jiang, Shibo, et al.
Publicado: (2013)

Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection
por: Geng, Qibin, et al.
Publicado: (2021)

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines
por: Jiang, Shibo, et al.
Publicado: (2012)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity
por: Gao, Yaning, et al.
Publicado: (2022)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4
por: Jiang, Shibo, et al.
Publicado: (2013)

Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells
por: Du, Lanying, et al.
Publicado: (2009)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
por: Du, Lanying, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5tffmovn7je4u87aqpk5d6ms9g